StudyRareStudyRare

Purine and pyrimidine metabolism

Log in to star
Nucleotides, heme, and glycosylation

Last updated Nov 4, 2026

Log in to add personal notes on this page.

Nucleotides, the building blocks of DNA and RNA, are made from scratch (de novo) or recycled from broken-down nucleic acids (salvage), and the excess is degraded. Purines (adenine, guanine) are degraded to uric acid, which is poorly soluble; pyrimidines (cytosine, uracil, thymine) leave less toxic end products. Dividing blood cells, lymphocytes, and the developing brain depend heavily on this metabolism, so these disorders present with anemia, immunodeficiency, or neurologic disease as well as with stones and gout. The mechanism differs by disorder: too few pyrimidines starve the marrow in hereditary orotic aciduria, while a toxic excess of a deoxynucleotide kills lymphocytes in ADA deficiency.

PRPP synthasePRPS1; the amount of PRPP sets therate of purine synthesisadenosine deaminaseADA; purine degradationADA deficiencypurine nucleoside phosphorylasePNPhypoxanthine-guaninephosphoribosyl-transferase, HGPRTHPRT1; with PRPP;salvage: recycles thebasesLesch-Nyhan syndromexanthine oxidaseneeds the molybdenumcofactor; allopurinolinhibits itthe de novo pyrimidine pathwayUMP synthase, one protein with twoactivitiesUMPS; with PRPP; via orotidinemonophosphatehereditary orotic aciduriathymidine phosphorylaseTYMP; pyrimidine breakdownMNGIEribose-5-phosphate+ ATPPRPPadenosine,deoxyadenosineinosine,deoxyinosinehypoxanthine,guanineIMP and GMPuric acidcarbamoyl phosphateorotic acidUMPthymidinethymine + 2-deoxy-ribose 1-phosphate
Figure: purine synthesis and degradation, forking at the purine bases between salvage by HGPRT and breakdown to uric acid, then pyrimidine synthesis and thymidine breakdown, with the four disorders at the steps they block.

Purines

  1. ribose-5-phosphate + ATP → PRPP: PRPP synthase (PRPS1). The amount of PRPP sets the rate of purine synthesis.
  2. Degradation: adenosine → inosine, deoxyadenosine → deoxyinosine: adenosine deaminase (ADA). Blocked in ADA deficiency.
  3. inosine → hypoxanthine: purine nucleoside phosphorylase (PNP).
  4. The purine bases fork. Salvage: hypoxanthine and guanine + PRPP → IMP and GMP: hypoxanthine-guanine phosphoribosyltransferase, HGPRT (HPRT1), which recycles purines that would otherwise be degraded. Blocked in Lesch-Nyhan syndrome.
  5. Breakdown: hypoxanthine and xanthine → uric acid: xanthine oxidase, which needs the molybdenum cofactor and is the enzyme allopurinol inhibits.

Pyrimidines

  1. carbamoyl phosphate → orotic acid, by the de novo pyrimidine pathway.
  2. orotic acid + PRPP → orotidine monophosphate → UMP: UMP synthase (UMPS), one protein with two activities. Blocked in hereditary orotic aciduria.
  3. Breakdown: thymidine → thymine + 2-deoxyribose 1-phosphate: thymidine phosphorylase (TYMP). Blocked in MNGIE, covered with the mitochondrial DNA disorders.
  • Lesch-Nyhan syndrome (X-linked): purine bases cannot be recycled, so the cell leans on de novo synthesis and degrades the unrecycled bases to uric acid. Uric acid precipitates as orange sand in diapers, stones, and gout. The brain disease (dystonia, intellectual disability, self-injury) is not fully understood; basal ganglia dysfunction is the leading explanation. Allopurinol lowers uric acid to protect kidneys and joints, and there is no cure for the neurologic disease.
  • ADA deficiency: deoxyadenosine and its nucleotides, above all dATP, build up; an expanded dATP pool interferes with DNA replication and drives lymphocytes into apoptosis, so T, B, and NK cells are markedly reduced. About 80% present in infancy with severe combined immunodeficiency; 15% to 20% present later with a milder combined immunodeficiency.
  • Hereditary orotic aciduria: orotic acid accumulates and pyrimidine nucleotides run short, so the marrow cannot make DNA fast enough: megaloblastic anemia in the first months of life that does not respond to B12 or folate. Oral uridine bypasses the block.
  • Also on this pathway, without a page here yet: PRPP synthase superactivity (PRPS1, X-linked), an overactive enzyme that makes too many purines, giving hyperuricemia, early gout, stones, and sometimes intellectual disability; and purine nucleoside phosphorylase deficiency (PNP), an autosomal recessive combined immunodeficiency.
  • Uric acid overproduction marks the purine salvage and PRPP disorders: a spot urine urate-to-creatinine ratio above 2 is characteristic of all HPRT1 disorders, even when serum uric acid looks only mildly raised.
  • Low or absent TRECs on newborn screening flag ADA-SCID along with other SCIDs; red cell ADA activity below 1% of normal and raised red cell deoxyadenosine nucleotides confirm it.
  • Urinary orotic acid needs context. Very high with megaloblastic anemia and normal ammonia is hereditary orotic aciduria; high with hyperammonemia is a urea cycle defect such as OTC deficiency, where unused carbamoyl phosphate spills into pyrimidine synthesis; mild and isolated can be a harmless UMPS carrier finding.
  • Plasma thymidine above 3 µmol/L or deoxyuridine above 5 µmol/L is diagnostic of MNGIE.

The pyrimidines are Cytosine, Uracil, and Thymine: "CUT the PY."